Does myoglobin protect Trypanosoma cruzi from the antiparasitic effects of nitric oxide?

P Ascenzi1, L Salvati, M Brunori

  • 1Department of Biology, University Roma Tre, Rome, Italy. ascenzi@bio.uniroma3.it

FEBS Letters
|July 27, 2001
PubMed

Insights

Trypanosoma cruzi, the parasite causing Chagas disease, may survive in heart cells by using myoglobin (Mb) to neutralize harmful nitric oxide (NO). This novel function of Mb protects the parasite from NO’s lethal effects.

Area of Science:

  • Parasitology
  • Cardiology
  • Biochemistry

Background:

  • Chagas disease, caused by Trypanosoma cruzi, leads to fatal cardiomyopathy in South and Central America.
  • The parasite preferentially colonizes cardiomyocytes, the heart muscle cells.

Purpose of the Study:

  • To investigate the potential role of myoglobin (Mb) in protecting Trypanosoma cruzi within cardiomyocytes.
  • To explore a novel function of Mb as a nitric oxide (NO) scavenger against parasite-toxic NO levels.

Main Methods:

  • The study is based on existing biochemical knowledge of Mb-NO interactions.
  • It postulates a mechanism involving ferrous oxygenated Mb reacting with NO to form nitrate.
  • It suggests an intracellular reductase regenerates active Mb.

Main Results:

  • Ferrous oxygenated Mb rapidly and irreversibly reacts with NO, producing nitrate.
  • This reaction yields ferric oxidized Mb, which can be reduced back to its active form.

Conclusions:

  • Myoglobin may protect Trypanosoma cruzi from the lethal effects of nitric oxide in cardiomyocytes.
  • This proposed Mb function is analogous to hemoglobin's protective role for Plasmodia in red blood cells.

Related Concept Videos

Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
American Trypanosomiasis01:22

American Trypanosomiasis

Chagas disease, or American trypanosomiasis, is a vector-borne parasitic infection caused by Trypanosoma cruzi, a flagellated protozoan (kinetoplastid) of the family Trypanosomatidae. The disease is endemic in Latin America, although cases are increasingly reported worldwide due to human migration. Transmission most commonly occurs when feces of infected triatomine bugs contaminate bite wounds or mucosal surfaces; additional routes include congenital, transfusional, transplant-related, and oral...
Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...